<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118585</url>
  </required_header>
  <id_info>
    <org_study_id>D00960</org_study_id>
    <nct_id>NCT01118585</nct_id>
  </id_info>
  <brief_title>Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)</brief_title>
  <official_title>Prospective Outcome Evaluation of Transoral Incisionless Fundoplication (TIF) for the Treatment of Gastroesophageal Reflux Disease (GERD): The TIF Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoGastric Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EndoGastric Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the safety and efficacy of TIF among a broad range of GERD
      patients treated in routine clinical practice at multiple centers across the United States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Effectiveness Endpoint: Typical and atypical GERD symptom elimination (scores ≤ 2 to
      each question) or clinically significant improvement (≥ 50% reduction in total scores) at
      6-month follow-up compared to baseline.

      Secondary Effectiveness Endpoints: GERD symptom elimination or clinically significant
      improvement at 12-month follow-up, 24-month follow-up and 36-month follow-up; complete
      discontinuation of PPIs; normalization of esophageal acid exposure; significant reduction in
      reflux episodes; healing of reflux esophagitis; reduction of hiatal hernia; safety supported
      by low incidence of serious adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastroesophageal Reflux Disease (GERD) symptom elimination</measure>
    <time_frame>6-month follow-up</time_frame>
    <description>GERD symptoms (typical and atypical) will be evaluated using three disease-specific standardized questionnaires: GERD-HRQL (Health-related Quality of Life), GSRS (GERD Symptom Rating Score), and RSI (Reflux Symptom Index).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination of Proton Pump Inhibitor (PPI) usage</measure>
    <time_frame>at 12-, 24- and 36-month follow-up</time_frame>
    <description>Elimination of Proton Pump Inhibitor (PPI) usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Esophageal acid exposure</measure>
    <time_frame>at 6-, 12-, 24- and 36-month follow-up</time_frame>
    <description>Normalization of esophageal acid exposure is defined as ≤ 4.3% of 24-hour period or ≤ 5.3% of 48-hour period at pH &lt; 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing of reflux esophagitis</measure>
    <time_frame>at 12, 24- and 36-month follow-up</time_frame>
    <description>Healing of reflux esophagitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>first 30 days</time_frame>
    <description>Incidence of anticipated and unanticipated adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Gastroesophageal Reflux Disease (GERD) symptom elimination</measure>
    <time_frame>at 12-, 24- and 36-month follow-up</time_frame>
    <description>GERD symptom elimination based on GERD-HRQL, GSRS and RSI scores.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Hiatal Hernia</condition>
  <arm_group>
    <arm_group_label>TIF Procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention: Transoral incisionless fundoplication procedure using the EsophyX device. During general anesthesia the EsophyX device is introduced trans orally into the stomach and used to created a 270 degree, 3cm in length, wrap at the distal end of the esophagus to treat GERD.. .</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TIF Procedure</intervention_name>
    <description>The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.</description>
    <arm_group_label>TIF Procedure</arm_group_label>
    <other_name>TIF - Transoral Incisionless fundoplication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  GERD for &gt; 1 year

          -  History of daily PPIs use for &gt; 6 months

          -  Moderate to severe typical or atypical GERD symptoms off PPIs

          -  Complete (responders) or partial (nonresponders) symptom control on PPIs

          -  Deteriorated gastroesophageal junction (Hill grade II or III)

          -  Proven gastroesophageal reflux by either endoscopy, ambulatory pH or barium swallow
             testing

          -  Willingness to undergo pH/impedance testing, if required

          -  Willingness to cooperate with the postoperative diet for 6 weeks

          -  Availability for follow up visits at 6 months and 12 months

          -  Willingly and cognitively signed informed consent

        Exclusion Criteria:

          -  BMI &gt; 35

          -  Incompletely reducible hiatal hernia with residual of &gt; 5 mm

          -  Esophagitis grade D

          -  Barrett's Esophagus &gt; 2 cm

          -  Esophageal ulcer

          -  Fixed esophageal stricture or narrowing

          -  Portal hypertension and/or varices

          -  Active gastro-duodenal ulcer disease

          -  Gastric outlet obstruction or stenosis

          -  Gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying
             study, if patient complains of postprandial satiety during assessment

          -  Coagulation disorder

          -  History of any of the following: resective gastric or esophageal surgery, antireflux
             surgery with anatomy unsuitable for TIF procedure per physician judgment, cervical
             spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia,
             scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis

          -  Pregnancy or plans of pregnancy in the next 12 months

          -  Enrollment in another device or drug study that may confound the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reginald CW Bell, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>SurgOne P.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mt. Graham Regional Medical Center</name>
      <address>
        <city>Safford</city>
        <state>Arizona</state>
        <zip>85546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tempe St. Luke's Hospital</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center and SurgOne P.C.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munroe Regional Hospital</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Indiana</state>
        <zip>46342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Livingston Hospital and Healthcare Services, Inc. CAH</name>
      <address>
        <city>Salem</city>
        <state>Kentucky</state>
        <zip>42078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Surgeons Group of Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegan Surgical Associates</name>
      <address>
        <city>Allegan</city>
        <state>Michigan</state>
        <zip>49010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossville Medical Group</name>
      <address>
        <city>Crossville</city>
        <state>Tennessee</state>
        <zip>38555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ihde Surgical Group, PA</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Master Center for Minimally Invasive Surgery</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah County Surgical Associates</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reston Hospital</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <zip>20190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.endogastricsolutions.com</url>
    <description>Click here for more information about this study: TIF Registry study</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>Esophagitis</keyword>
  <keyword>Fundoplication</keyword>
  <keyword>Anti-reflux surgery</keyword>
  <keyword>PPI dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Hernia, Hiatal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

